Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001254:Astrocytoma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005347:Fibroblasts / Q000187:drug effects; D006027:Glycosides / Q000009:adverse effects*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007783:Lactones / Q000009:adverse effects; D007890:Leiomyosarcoma / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011035:Podophyllum; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D006027:Glycosides; D007783:Lactones; D013876:Thiophenes